- Contact Us
- Locations & Directions
- Medical Staff Directory
- Careers
- Giving
- International Patients




Find a Clinical Trial by Adult Cancer Type
-
Back to Adult Cancers
Cancer Type: Esophagus
44 protocol(s) meet the specified criteria. Please click on the protocol number to get more information about the trial.
Doctor | Protocol No. | Title |
---|---|---|
Asher, Arash | IIT2019-08-ASHER-VOXXSOCK | IIT2019-08-ASHER-VOXXSOCK: Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy: A Double Blind, Randomized, Controlled Crossover Trial (IRB #236) |
Balmanoukian, Ani | 204691 | 204691: A Phase I Open Label study of GSK3359609 administered alone and in combination with anticancer agents in subjects with selected advanced solid tumors (IRB:54166) |
Balmanoukian, Ani | AB154CSP0001 | AB154CSP0001: A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants with Advanced Malignancies (IRB#57210) |
Chiu, Vi K. | DEK-DKK1-P205 | DEK-DKK1-P205: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish) (IRB#782) |
Gresham, Gillian | IIT2018-19-GRESH-DIGISTEP | Digitally-captured Step counts for Evaluating Performance Status in Advanced Cancer Patients: A single cohort, prospective trial (Digi-STEPS) (IRB#55271) |
Gresham, Gillian | IIT2020-13-GRESHAM-ELLY | IIT2020-13-GRESHAM-ELLY: Evaluating the effect of a mobile audio companion (Elly) to reduce anxiety in cancer patients (IRB#943) |
Gutierrez, Rodolfo | IMC-C103C-101 | A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A*0201-positive Patients with Advanced MAGE-A4-positive Cancer (IRB#56562) |
Gutierrez, Rodolfo | TYR-219-01 | A Phase 1/2 Study with Open-Label, Dose Escalation Phase Followed by Single-Arm Expansion at the Maximum Tolerated Dose to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of NT219 Injection alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced solid tumors and Head and Neck cancer (IRB#907) |
Hamid, Omid | TAPUR | Targeted Agent and Profiling Utilization Registry (TAPUR) Study (IRB#49119) |
Hamid, Omid | ALKS4230-001 | ALKS4230-001: A Phase 1/2 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors- ARTISTRY-2 (001)(IRB#0539) |
Hamid, Omid | RTX-240-01 | PHASE 1/2 STUDY OF RTX-240 MONOTHERAPY (IRB#596) |
Hamid, Omid | TWT-101 | TWT-101: A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies (IRB#819) |
Hamid, Omid | R3767-ONC-1613 | R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies (IRB#48031) |
Hamid, Omid | BDB001-102 | BDB001-102 : A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors (IRB#397) |
Hamid, Omid | NC318-01 | NC318-01: A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors (IRB#54833) |
Hamid, Omid | CIBI322A102 | CIBI322A102 A Phase 1a study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with advanced malignant tumors. (IRB#1021) |
Hamid, Omid | D8510C00001 | D8510C00001: A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid Tumors (IRB#57295) |
Hamid, Omid | 587-00 | 587-00: A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. (IRB#54410) |
Hamid, Omid | 212214 | 212214: A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors (IRB#688) |
Hamid, Omid | BA3011-001 | BA3011-001: A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients with Advanced Solid Tumors( IRB#383) |
Hendifar, Andrew | 18-0402 | 18-0402: A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects with Advanced Solid Tumors and Pancreatic Cancer using Combination Therapy (IRB#0185) |
Hendifar, Andrew | MK-7339-002 | MK7339-002: A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (IRB#57241) |
Hendifar, Andrew | RGX-202-001 | RGX-202-001: A Phase 1 Study of RGX-202-01, a Small Molecule Inhibitor of the Creatine Transporter, SLC6a8, with or without FOLFIRI in Patients with Advanced Gastrointestinal Malignancies with Select Expansion Cohorts (IRB#55176) |
Hendifar, Andrew | XMAB18087-01 | XmAb18087-01: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects with Advanced Neuroendocrine and Gastrointestinal Stromal Tumors (IRB#52197) |
Hitchins, Megan | IIT2017-13-HITCHINS-UCFC | IIT2017-13-HITCHINS-UCFC: Identifying cryptic causes for high-risk hereditary cancer syndromes and their role in cancer causation. (IRB#49624) |
Labadzhyan, Artak | IIT2016-09-LABADZHYAN-ICI | IIT2016-09-LABADZHYAN-ICI: Prospective study of predictive markers and changes in specific endocrine hormones in patients with metastatic cancers treated with immune checkpoint inhibitors. (IRB#45026) |
Mita, Alain | BNT411-01 | BNT411-01: Phase 1/2a, first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC) (IRB#578) |
Mita, Monica | 8379643 | 8379643: A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Evidence of Antitumor Activity of ZZ06 in Adult Patients with Advanced EGFR positive Solid Tumor Malignancies (IRB#632) |
Mita, Monica | SQZ-PBMC-HPV-101 | SQZ-PBMC-HPV-101: A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination with Atezolizumab in HLA-A*02+ Patients with HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors (IRB#577) |
Mita, Alain | ASTX029-01 | ASTX029-01: A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors (IRB#54467) |
Mita, Monica | OBT076-001 | OBT076-001: A Phase 1, open-label, dose finding study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of OBT076, a CD205-directed antibody drug conjugate, in recurrent and/or metastatic CD205-positive solid tumors and in women with CD205-positive HER2-negative metastatic breast cancer (IRB#076) |
Mita, Alain | P1719-SUR-Z11 | P1719-SUR-Z11: A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab, in Subjects with Selected Advanced and Recurrent Solid Tumours. (IRB#57155) |
Mita, Monica | MT-5111-001 | MT-5111_001: A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors (IRB#144) |
Mita, Monica | M16-573 | M16-573: A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid tumors (IRB#24) |
Mita, Monica | LNS-101 | LNS-101: A Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer (IRB#315) |
Mita, Monica | INCB106385-102 | INCB106385-102: A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors (IRB#1094) |
Mita, Monica | GEN-602-CT-101 | GEN-602-CT-101: A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Given orally on a daily x 21 days followed by 7 Days off schedule in patients with Advanced Solid Tumors or Lymphoma (IRB#56184) |
Posadas, Edwin | BB-UOP-42197-BLOOD-BANK | Urologic Oncology Program Blood Specimen Repository (IRB # 42197) |
Reckamp, Karen | ELVCAP-001-01 | ELVCAP-001-01: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (IRB#862) |
Shiao, Stephen | IIT2016-18-SHIAO-NEOADSRS | IIT2016-18-SHIAO-NEOADSRS: Neoadjuvant radiosurgery for the treatment of metastatic brain tumors (IRB#47027) |
Sicotte, Nancy | BA39731 | BA39731: An Observational Study of Ocrelizumab-Treated Patients With Multiple Sclerosis to Determine the Incidence and Mortality Rates of Breast Cancer and All Malignancies (Verismo Study) (IRB#482) |
Wentzel, Kristopher | 9801-CL-0101 | 9801-CL-0101: A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors (IRB#57758) |
Wentzel, Kristopher | 8951-CL-0103 | A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression. (IRB#52384) |
Wentzel, Kristopher | XL184-021 | XL184-021: A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors (IRB#56332) |
- Brain and Nervous System
- Kidney
- Leukemia
- Melanoma
- Non-Hodgkin's Lymphoma
- Ovary
- Pancreas
- Prostate
- Sarcoma
- Small Intestine
New studies open frequently, please check back for updates
- Amersi, Farin
- Arditi, Moshe
- Asher, Arash
- Ayoub, Walid
- Bae, Hyun
- Balmanoukian, Ani
- Basho, Reva
- Boin, Francesco
- Burch, Miguel
- Burford, Matthew
- Burnison, Michele
- Burwick, Richard
- Cass, Ilana
- Chaux, George
- Chen, Peter
- Chiu, Vi K.
- Chung, Alice
- Chung, Jeffrey
- Danovitch, Itai
- Darrah, Justin
- Daskivich, Timothy
- Esmailian, Fardad
- Faries, Mark
- Figlin, Robert
- Figueiredo, Jane
- Fleshner, Phillip
- Freedland, Stephen
- Friedman, Oren
- Gaddam, Srinivas
- Garcia, Maurice
- Gaultier, Cyril
- Gayther, Simon
- Ghandehari, Sara
- Giuliano, Armando
- Gong, Jun
- Goodarzi, Mark
- Goodman, Marc
- Gresham, Gillian
- Gupta, Amit
- Gutierrez, Rodolfo
- Hage, Antoine
- Hamid, Omid
- Hendifar, Andrew
- Hitchins, Megan
- Ho, Allen
- Hu, Jethro
- Huang, Edmund
- Jordan, Stanley
- Kamil, Elaine
- Kim, Hyung
- Kulber, David
- Labadzhyan, Artak
- Lawrenson, Kate
- Lewis, Richard
- Liu, Gene
- Liu, Quin
- Lo, Simon
- Majlessipour, Fataneh
- Makkar, Rajendra
- Mandelbaum, Bert
- McArthur, Heather
- Mehmi, Inderjit
- Merin, Noah
- Mita, Alain
- Mita, Monica
- Moser, Franklin
- Natale, Ronald
- Noureddin, Mazen
- Osipov, Arsen
- Pandol, Stephen
- Paquette, Ronald
- Paski, Shirley
- Patel, Jignesh
- Posadas, Edwin
- Rader, Florian
- Reckamp, Karen
- Rimel, Bobbie Jo
- Rokhsar, Sepehr
- Rosenbloom, Barry
- Rudnick, Jeremy
- Sandler, Howard
- Sankhala, Kamalesh
- Scher, Kevin
- Scott, Victoria
- Shiao, Stephen
- Sicotte, Nancy
- Stone, Michael
- Sundaram, Vinay
- Syal, Gaurav
- Tagliati, Michele
- Tajbakhsh, Jian
- Tan, Echo
- Tapson, Victor
- Toossi, Shahed
- Wachsman, Ashley
- Wentzel, Kristopher
- Yang, Ju Dong
- Zumsteg, Zachary
The following physicians have trials which are currently recruiting patients. If you do not see the doctor you are searching for, please call 310-423-2133 for more information.
- 5-fluorouracil
- ALKS 4230
- AMG 650
- ASTX295
- AZD-2281
- AZD9291
- Ado-trastuzumab Emtansine
- Adriamycin
- Adrucil
- Afatinib
- Alimta
- Apalutamide
- BA3011
- BAY 1747846
- BNT411
- Blinatumomab
- CART-TnMUC1
- CDX-301
- CPT-11
- CPX-351
- Cabozatinib
- Camptosar
- Capecitabine
- Carboplatin
- Cerubidine
- Cetuximab
- Cyclophosphamide
- Cytarabine
- Cytosar
- Cytoxan
- DKN-01
- DPX-Survivac
- DSP-7888
- Dabrafenib
- Daunorubicin
- Decadron
- Defactinib
- Dexamethasone
- Doxorubicin
- Eloxatin
- Erbitux
- Etoposide
- GC4419
- GSK3359609
- GSK6097608
- Gefitinib
- Gemtuzumab ozogamicin
- Gemzar
- Gilotrif
- Herceptin
- Hiltonol
- IBI322
- IMC-C103C
- INCB106385
- INCMGA00012
- INO-5151
- Ibuprofen
- Inotuzumab Ozogamicin
- Ipilimumab
- Iressa
- Itraconazole
- JNJ-61186372
- JNJ-73841937
- LOAd703
- LTT462
- LXH254
- LY3475070
- Lovaza
- Lumason
- MDX-101
- MEDI1191
- MK-7684
- Mercaptopurine
- Methotrexate
- Motrin
- Mutamycin
- NA
- NC318
- NKTR-214
- NT219
- NanoPac
- Necitumumab
- Neoprofen
- Nivolumab
- Olaparib
- Omega-3 Fatty Acid
- Oncaspar
- Onivyde
- Oxaliplatin
- PT2977
- Paraplatin
- Pegaspargase
- Pembrolizumab
- Pemetrexed
- Platinol
- Prednisone
- Purinethol
- RTX-240
- Rifadin
- Rifampin
- SGN-1-LIV1A
- SQL70
- SQP33
- Savolitinib
- Sporanox
- Sunitinib
- Sutent
- TBX-3400
- Tabloid
- Tazemetostat
- Thioguanine
- Tislelizumab
- Tocilizumab
- Trametinib
- Trastuzumab
- VS-6063
- Vepesid
- Vincristine
- XL-184
- Xeloda
- Yervoy
- alectinib
- atezolizumab
- avasopasem manganese
- bempegaldesleukin
- cisplatin
- clazakizumab
- crizotinib
- dostarlimab
- durvalumab
- enfortumab vedotin
- gadobutrol
- gemcitabine
- irinotecan
- lenvatinib
- leucovorin
- liposomal cytarabine-daunorubicin
- mFOLFIRINOX
- mRNA-4157
- mitomycin
- osimertinib
- poly-ICLC
- ribociclib
- selpercatinib
- seribantumab
- stereotactic body radiation therapy (SBRT)
- tucatinib
- Phase I